Latest ABT news and sentiment

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this maker of infant formula, medical devices and drugs have returned -7.1%, compared to the Zacks S&P 500 composite's -2% change. During this period, the Zacks Medical - Products industry, which Abbott falls in, has lost 7.3%. The key question now is: What could be the stock's future direction? While media releases or rumors about a substantial change in a company's busine

Abbott garners FDA nod for its TactiFlex catheter to treat AFib

Abbott has received FDA clearance for its TactiFlex Duo ablation catheter, designed to treat atrial fibrillation (AFib). This latest-generation catheter offers physicians more flexibility by utilizing pulsed field ablation, radio frequency energy, or a combination of both. The approval, based on positive outcomes from the FlexPulse Identity study, marks Abbott's fifth electrophysiology regulatory nod in just over a year, with a U.S. rollout expected soon.

Here's Why Abbott (ABT) Fell More Than Broader Market

Abbott (ABT) closed at $105.52 in the latest trading session, marking a -2.59% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.58% for the day. At the same time, the Dow lost 1.18%, and the tech-heavy Nasdaq lost 0.32%. The maker of infant formula, medical devices and drugs's stock has dropped by 0.27% in the past month, falling short of the Medical sector's gain of 2.73% and outpacing the S&P 500's loss of 0.36%. The investment community will be closely monitoring the performance of Abbott in its forthcoming earnings report. It is anticipated that th

Abbott Laboratories stock holds firm after July earnings

Abbott Laboratories stock holds valuation premium amid steady earnings

Abbott Laboratories' stock maintains a valuation premium, with a trailing P/E ratio around 35.05, driven by steady earnings growth and a robust product portfolio in diagnostics and medical devices. The company's valuation metrics, including a price-to-book ratio of 3.68 and a PEG ratio of 1.99, reflect its status as a quality growth healthcare stock, with investors valuing its diversified earnings and future expansion opportunities. Its broad portfolio across diagnostics, cardiovascular, diabetes devices, and nutritional products ensures stable revenue and underpins this premium.

Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets

This article identifies Abbott Laboratories (ABT), UnitedHealth Group (UNH), and Bunge Global (BG) as defensive dividend stock picks for investors seeking stability in uncertain markets. These companies offer a combination of income, moderate risk profiles, and measured volatility, making them attractive amidst inflation, Fed decisions, and energy cost concerns. The analysis provides an overview of each company's operations, market cap, and specific factors that make them suitable defensive investments, while also highlighting potential risks.

How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story

Abbott Laboratories recently received FDA authorization for its Libre Duo 10 Day sensor, advanced its TactiFlex Duo AFib ablation catheter, launched a new Similac product, and partnered on a colorectal cancer screening education hub. These advancements extend Abbott's reach across key healthcare sectors, but the core investment narrative remains focused on managing diabetes pricing pressures and ongoing litigation. While these innovations reinforce Abbott's growth story, the primary short-term factors influencing its valuation are competitive pricing in diabetes and legal challenges.

Abbott Laboratories stock edges higher as investors digest tax-related insider transaction and cyber

Abbott Laboratories VP John A. McCoy Jr. Reports Share Sales on September 1-2, 2026

John A. McCoy, Jr., Vice President and Controller of Abbott Laboratories (NYSE:ABT), reported two stock transactions on September 3, 2026, stemming from sales on September 1 and 2. These included the disposal of 52 common shares for tax obligations at $110.36 each and the open-market sale of 27 common shares at $109.54 each. Following these transactions, McCoy directly holds 24,549 shares and indirectly holds 59 shares through a company trust.

Abbott Laboratories stock underperforms Thursday when compared to competitors

Shares of Abbott Laboratories (ABT) fell by 1.52% on Thursday, closing at $108.79, despite a strong overall market performance where the S&P 500 Index and Dow Jones Industrial Average both saw gains. The company's stock closed 20.87% below its 52-week high of $137.49, which was achieved on September 22nd.

Nifty Pharma Today: Down 1.45% at Close

The Nifty Pharma index closed 1.45% lower today, making it the top losing sector. The decline was widespread, with 13 out of 20 displayed pharma stocks falling, although some heavyweights like Dr. Reddy's Laboratories and Cipla managed to post gains. Investors are advised to monitor key stocks for potential shifts in market participation in the next session.

Abbott Introduces America’s First Liquid Baby Formula With Whole Milk

Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

How Abbott Labs Is Embracing RFK Jr.'s Make America Healthy Again Movement

Abbott Laboratories is leaning into the Make America Healthy Movement, launching a new infant formula made with whole milk. Continue Reading

What Is Abbott Laboratories (ABT) Telling Investors With Its New Infant Formula?

Abbott Laboratories (NYSE:ABT) launched Similac 360 Total Care Made With Whole Milk, a commercially sterile ready-to-feed liquid infant formula made with whole milk in the U.S. The product is the first of its kind in the U.S. market to combine whole milk with a ready-to-feed liquid format. The formula uses whole milk and a blend of human milk oligosaccharides to more closely mirror key elements of breast milk. The launch expands Abbott's infant nutrition portfolio and targets parents seeking convenient, nutritionally advanced formula options. For readers interested in more companies geared tow

National Advertising Division Finds Certain Kendamil Infant Formula Claims Supported; Recommends Others Be Modified or Discontinued

BBB NATIONAL PROGRAMS In a challenge brought by Abbott Laboratories, BBB National Programs' National Advertising Division determined that Kendal Nutricare Limited provided support for certain claims about the use of whole milk in its Kendamil infant formula. However, the National Advertising Division (NAD) recommended that Kendal modify or discontinue claims regarding the product's nutritional benefits, ingredients, and heritage. New York, NY, Aug. 31, 2026 (GLOBE NEWSWIRE) -- In a challenge brought by Abbott Laboratories, BBB National Programs' National Advertising Division determined that Ke

Abbott Laboratories Introduces Similac 360 Total Care Made With Whole Milk in US

Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula

New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support baby's natural defenses—making it Similac's closest formula to breast milk Abbott's liquid-only launch reflects growing parent interest in infant formulas made with whole milk while offering the convenience and reassurance that comes with commercially sterile, ready-to-feed formula Product is available at prices similar to the per-feeding cost of powdered Similac 360 Total Care and is available onlin

Dexcom, Abbott await Medicare coverage expansion for CGMs

Dexcom and Abbott are anticipating a significant expansion in Medicare coverage for continuous glucose monitors (CGMs) to include people with Type 2 diabetes who do not take insulin. This change could broaden access to their glucose sensors for millions of Americans, potentially reshaping diabetes care. Dexcom CEO Jake Leach and Abbott CEO Robert Ford both view this as a major market opportunity, with Dexcom estimating 25 million non-insulin-using Type 2 diabetics and Abbott expecting 10 million more Medicare recipients to become eligible.

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

Abbott Laboratories received FDA authorization for its Libre Duo 10 Day, the first wearable device to continuously monitor glucose and detect rising ketone levels, targeting an existing ecosystem of 8 million users. Despite this regulatory milestone, Abbott's stock has underperformed competitors like Dexcom, leading to questions about whether this innovation can drive a significant re-rating. The article suggests that broader Medicare reimbursement for Type 2 diabetes patients and integration with insulin pumps will be crucial catalysts for the stock's recovery.